CLINICAL TRIAL ANALYSIS

Study ID: CT-2024-089-B | Phase III Analysis
Report Date: October 24, 2023

Total Participants 1,240
Duration 18 Months
Primary Endpoint 92.4% Efficacy
Safety Status Cleared

Outcome Measure	Placebo (n=620)	Treatment (n=620)	Difference (%)	P-Value
Symptom Reduction (Day 14)	14.2%	68.5%	+54.3%	**< 0.001**
Patient Recovery Rate	44.1%	89.2%	+45.1%	**< 0.001**
Adverse Events (Grade 3+)	2.1%	2.4%	+0.3%	0.842
Secondary Biomarker A	112 mg/dL	84 mg/dL	-25.0%	**0.004**

Clinical Observations & Interpretations

[Insert Qualitative Analysis Here]

Confidential - For Internal Medical Review Only - Generated by Biostatistics Dept.